This page holds a finished NU 636 Unit 2 prescribing rationale naming the reasonable alternatives, the patient factor that decided between them, and the monitoring that follows. Searches like "nu 636 unit 2 assignment example", "nu636 unit 2 sample" and "nu 636 unit 2 example" land here.
The NU 636 Unit 2 prescribing rationale, in full
Prescribing Rationale for an Acute Gout Flare in a 66-Year-Old Man With Stage 3b Kidney Disease on an Anticoagulant
Student Name
Department of Nursing, Herzing University
NU 636: Advanced Pharmacology
Instructor Name
January 28, 2026
Prescribing Rationale for an Acute Gout Flare in a 66-Year-Old Man With Stage 3b Kidney Disease on an Anticoagulant
The Patient and the Problem
Mr. N., a composite 66-year-old retired postal carrier, presents with 20 hours of severe pain, swelling, and redness of the right first metatarsophalangeal joint. He had two similar episodes in the past three years, each treated elsewhere with naproxen. He has chronic kidney disease stage 3b, with an estimated glomerular filtration rate of 38 mL/min/1.73 m2 on labs from last month, hypertension, and atrial fibrillation. His medications are apixaban 5 mg twice daily, atorvastatin 40 mg daily, amlodipine 10 mg daily, and hydrochlorothiazide 12.5 mg daily. He has no diabetes and no history of peptic ulcer. His temperature is 99.3 F, and the joint is too tender to bear the weight of a sheet. The presentation is typical of a gout flare, and he has a documented prior diagnosis with crystals seen on aspiration four years ago. Infection is considered and judged unlikely given his typical history, recurrence, and lack of systemic toxicity, with a plan to aspirate if he does not improve as expected.
The goal is rapid relief of the flare within days, with the fewest adverse effects in a man whose kidney function and anticoagulant narrow every option.
The Candidate Agents
Three drug classes are recommended as first-line options for a gout flare, and the choice among them is meant to be made on patient factors (FitzGerald et al., 2020). A nonsteroidal anti-inflammatory drug such as naproxen would offer fast relief and is the agent he has used before with success. Colchicine would offer an effective oral option that works best when started within 36 hours of onset, which he is inside. An oral glucocorticoid such as prednisone would offer relief equivalent to a nonsteroidal anti-inflammatory drug, shown in a randomized trial comparing prednisolone with naproxen (Janssens et al., 2008). An intra-articular glucocorticoid injection is a fourth reasonable option for a single large joint. Interleukin-1 inhibitors are reserved for patients in whom all of these are ineffective or contraindicated, and because Mr. N. has usable options among the first-line agents, that class is not part of today's decision. Naming it, and the reason it is set aside, keeps the list of candidates honest rather than conveniently short.
Elimination, One Agent at a Time
Naproxen is eliminated first, for two reasons drawn from the case. Nonsteroidal anti-inflammatory drugs reduce renal prostaglandin synthesis, which the kidney relies on to maintain blood flow when function is already reduced; in a man with an eGFR of 38 who also takes a thiazide diuretic, a course of naproxen risks an acute decline in kidney function. And nonsteroidal anti-inflammatory drugs impair platelet function and injure gastric mucosa, adding substantially to the bleeding risk of apixaban. The fact that it worked before does not outweigh a risk that has increased since then.
Colchicine is eliminated second, although it is closer. At his kidney function it can be used for a flare, but the margin between effective and toxic doses is narrow, and colchicine is a substrate of cytochrome P450 3A4 and P-glycoprotein. His atorvastatin is metabolized by the same enzyme, and combined use in reduced kidney function has been associated with myopathy (Rosenthal & Burchum, 2021). None of these factors is an absolute bar alone, but together, and in a man who wants to avoid another laboratory visit, they make colchicine the riskier of the two remaining options.
The intra-articular injection is kept as an alternative rather than eliminated. It avoids systemic effects entirely, but it requires an appointment for the procedure, and the patient's anticoagulant raises the bleeding risk of joint aspiration and injection somewhat, though it is not usually a contraindication. He prefers to start treatment today at home, and his preference is a legitimate factor in a choice between options of similar effectiveness.
The Chosen Agent: Dose, Route, Frequency, and Duration
Prednisone 35 mg by mouth once daily with breakfast for 5 days, then stop, dispense 25 mg and 10 mg tablets as needed to make the dose, no refills. The dose and duration follow the regimen shown by Janssens et al. (2008) to be equivalent in pain relief to naproxen, and a short course of five days does not require a taper. Oral glucocorticoids need no dose adjustment for kidney function, they do not interact meaningfully with apixaban through the coagulation pathway, and a short course carries low risk in a man without diabetes. Morning dosing reduces sleep disturbance. He is advised to take it with food, to expect a possible increase in appetite or mild mood change, and to use ice and elevate the foot.
The thiazide is addressed as part of the rationale, not left untouched. Thiazide diuretics raise serum urate and increase the risk of recurrent flares. Changing his antihypertensive regimen is not urgent today, but a plan is made to consider replacing hydrochlorothiazide at the follow-up visit, in coordination with his blood pressure goals.
Monitoring
Baseline: blood pressure and a fingerstick glucose today, because glucocorticoids can raise both. A telephone check at 48 to 72 hours asks whether pain has improved by at least half. Temperature is recorded at that call; a fever above 100.4 F, spreading redness, or worsening pain would prompt same-day review and joint aspiration to exclude septic arthritis. A serum urate is drawn two to four weeks after the flare settles, when it more accurately reflects his baseline, along with creatinine.
What Would Change the Plan
If pain has not improved by half at 72 hours, the diagnosis is reconsidered first, and the joint is aspirated, before any change of drug. If the flare is confirmed and resistant, intra-articular injection becomes the next step. If his glucose rises above 200 mg/dL on prednisone, the course is shortened and colchicine at a reduced dose becomes the alternative, with atorvastatin temporarily held. If he has two or more flares a year, which his history suggests he is approaching, he meets the threshold for urate-lowering therapy, and allopurinol, started at a low dose appropriate for his kidney function and titrated to a serum urate below 6 mg/dL, would be discussed at the follow-up visit (FitzGerald et al., 2020). Treating the flare and preventing the next one are separate decisions, and this rationale covers only the first while naming when the second begins.
References
FitzGerald, J. D., Dalbeth, N., Mikuls, T., Brignardello-Petersen, R., Guyatt, G., Abeles, A. M., Gelber, A. C., Harrold, L. R., Khanna, D., King, C., Levy, G., Libbey, C., Mount, D., Pillinger, M. H., Rosenthal, A., Singh, J. A., Sims, J. E., Smith, B. J., Wenger, N. S., ... Neogi, T. (2020). 2020 American College of Rheumatology guideline for the management of gout. Arthritis Care & Research, 72(6), 744-760. https://doi.org/10.1002/acr.24180
Janssens, H. J. E. M., Janssen, M., van de Lisdonk, E. H., van Riel, P. L. C. M., & van Weel, C. (2008). Use of oral prednisolone or naproxen for the treatment of gout arthritis: A double-blind, randomised equivalence trial. The Lancet, 371(9627), 1854-1860. https://doi.org/10.1016/S0140-6736(08)60799-0
Rosenthal, L. D., & Burchum, J. R. (2021). Lehne's pharmacotherapeutics for advanced practice nurses and physician assistants (2nd ed.). Elsevier.
What a finished NU 636 Unit 2 prescribing rationale looks like
The finished rationale spends more space on the agents that were not chosen than most versions spend on the one that was. Two or three defensible options appear early with what each would offer this composite patient, and then each is eliminated for a stated reason drawn from the case rather than from preference. The deciding factor is isolated and named, whether that is renal function, a documented allergy, pregnancy status, an interaction with an existing medication or a coverage constraint. Dose, route, frequency and duration arrive together, each with a justification rather than a citation to a table. Monitoring carries intervals. A short final section states the conditions under which the plan changes, including what would prompt a switch and what would prompt stopping altogether.
How a NU 636 Unit 2 example is structured
The example is ordered so the decision arrives last rather than first. It opens with the composite patient and the problem being treated, stated in the terms that will matter later, which means the history includes the factors the rationale intends to use. The second section lays out the candidate agents, each with the reason it belongs in the conversation, because eliminating options nobody would consider proves nothing. The third section performs the elimination, one agent at a time, tying every exclusion to something in the case. The fourth commits to the agent and sets out dose, route, frequency and duration with the reasoning attached to each. The fifth builds monitoring, with a baseline, an interval and a threshold for action. The closing section names what would change the plan, which is the part most versions never write.
Alternatives named before the choice
Several defensible agents appear first, since a rationale that presents one option has described a prescription rather than defended a decision.
One patient factor doing the deciding
Kidney function, an allergy, a pregnancy or an interaction is isolated as the reason the field narrowed, and it is drawn from the case.
Dose, route and duration justified together
Each element carries its own reasoning, so the duration is defended by the condition rather than copied from a reference table without comment.
Monitoring with a stated interval
The rationale names the baseline, the recheck point and the value that would trigger action, which makes the plan something a clinician could follow.
The conditions that would change it
A closing section states what result, response or new information would prompt a switch, a dose change or stopping the agent entirely.
Where marks go in NU 636 Unit 2
A rationale that names the right agent can still score poorly, and that surprises people every term. The largest loss is an undefended choice: the correct drug, correctly dosed, with nothing explaining why the alternatives lost. Listing alternatives without eliminating them is the same failure wearing a disguise, since a mention is not an argument. Patient factors carried in the case and then ignored in the decision cost heavily, because the case was built around them. Duration stated without reasoning, and monitoring stated without an interval, each leave a criterion untouched. Rationales that never define a recheck point or a switching condition stop halfway through the thinking the course wants. Sources that are out of date undercut everything above them.
Get a NU 636 Unit 2 example written to your instructions
Send the Unit 2 instructions and the rubric from your NU 636 classroom, plus the case or the condition the rationale has to address. We write a custom example against those criteria, with the alternatives eliminated on the evidence and monitoring given intervals, and return it in 24 to 48 hours. The first custom sample is free.
NU 636 Unit 2 questions, answered
How many alternatives should the rationale consider?
Enough to make the decision look contested, which is usually two or three besides the agent selected. Each has to be genuinely defensible for this patient, because eliminating a poor option demonstrates nothing. More than four tends to thin the reasoning, since every candidate needs a stated reason for entering the conversation and a stated reason for leaving it.
Can I cite clinical guidelines in this course?
In most sections yes, and they are often expected for anything with an established standard of care. What loses marks is citing a guideline in place of reasoning, as though the recommendation ends the discussion. Use the guidance to establish what is reasonable, then do the work the guidance cannot do, which is applying it to the specific factors in your composite patient.
What counts as a reassessment trigger?
Anything that would honestly move the plan: a laboratory result crossing a defined value, an adverse effect appearing, a lack of response by a stated point, a new interacting medication or a change in organ function. Name the trigger and the response together. A trigger with no consequence attached reads as a hedge instead of the clinical thinking being asked for.